STUDY OBSERVATIONAL OF ERLOTINIB AS SECOND LINE TREATMENT IN PATIENTS WITH SQUAMOUS NSCLC AND EGFR NATIVE
NCT02328391
·
clinicaltrials.gov ↗
UNKNOWN
Status
51
Enrollment
OTHER
Sponsor class
Conditions
Carcinoma, Squamous Cell
Sponsor
Grupo Gallego de Cancer de Pulmon